– USA, MA – Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, announced the appointment of Dr. Sunil Agarwal (M.D.) to its Board of Directors.
“It is a pleasure to welcome Sunil to our Board of Directors. His extensive drug development and clinical expertise strongly complements our Board’s skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage clinical development with the goal of STAR-0215 becoming the market leader in hereditary angioedema,” said CEO, Dr. Jill Milne.
About Dr. Sunil Agarwal
Dr. Sunil Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
“I am excited to join the Board at Astria at this important stage as the organization prepares for Phase 3 development of STAR-0215,” said Dr. Sunil Agarwal. “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics. Throughout his career, Dr. Agarwal has served in leadership and executive roles in the biopharmaceutical industry. He most recently served as EVP and CDO for Sana Biotechnology and, before that, as President of Research and Development at Juno Therapeutics until its acquisition by Celgene. At Ultragenyx he served as EVP and CMO and at Genentech as SVP and Global Development Head. He has led global approvals across multiple indications for Rituxan, Actemra, Xolair, Lucentis, Ocrevus, Mepsevii, Breyanzi, and Gliadel.
Dr. Agarwal holds a B.S. in neurobiology from Cornell University and earned his M.D. from Tufts University School of Medicine. He completed his residency at Children’s National Medical Center, Washington, D.C., and practiced in the CNMC Pediatric Emergency Department.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis.
SOURCE: https://astriatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
